Arenaviruses: Lassa fever, Lujo hemorrhagic fever, lymphocytic choriomeningitis, and the south american hemorrhagic fevers

Viral Infections of Humans: Epidemiology and Control

Volumn , Issue , 2014, Pages 147-171

  Bausch, Daniel G ^a   Mills, James N ^b  

^a TULANE UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929899448     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4899-7448-8_8     Document Type: Chapter

References (210)

1. Murphy FA, Whitfield SG. Morphology and morphogenesis of arenaviruses. Bull World Health Organ. 1975;52:409-19.
2. Bond NG, Moses LM, Peterson AT, Mills JN, Bausch DG. Environmental aspects of the viral hemorrhagic fevers. In: Friis R, editor. Praeger handbook of environmental health. Santa Barbara: Praeger Publishing Company; 2012. p. 133-61.
3. Paweska JT, Sewlall NH, Ksiazek TG, et al. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis. 2009;15:1598-602.
4. de Bellocq JG, Borremans B, Katakweba A, et al. Sympatric occurrence of 3 arenaviruses, Tanzania. Emerg Infect Dis. 2010;16:692-5.
5. Gunther S, Hoofd G, Charrel R, et al. Mopeia virus-related arenavirus in natal multimammate mice, Morogoro, Tanzania. Emerg Infect Dis. 2009;15:2008-12.
6. Palacios G, Savji N, Hui J, et al. Genomic and phylogenetic characterization of Merino Walk virus, a novel arenavirus isolated in South Africa. J Gen Virol. 2010;91:1315-24.
7. Wulff H, McIntosh BM, Hamner DB, Johnson KM. Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa. Bull World Health Organ. 1977;55:441-4.
8. Digoutte JP, Gagnard VJ, Bres P, Pajot FX. Nyando virus infection in man. Bull Soc Pathol Exot Filiales. 1972;65:751-8.
9. Gonzalez JP, McCormick JB, Saluzzo JF, Georges AJ. African viral haemorrhagic fevers. Studies in the Central African Republic. Ent med et Parasitol. 1983;21:119-30.
10. Kiley MP, Swanepoel R, Mitchell SW, Lange JV, Gonzalez JP, McCormick JB. Serological and biological evidence that Lassacomplex arenaviruses are widely distributed in Africa. Med Microbiol Immunol (Berl). 1986;175:161-3.
11. Johnson KM, Taylor P, Elliott LH, Tomori O. Recovery of a Lassarelated arenavirus in Zimbabwe. Am J Trop Med Hyg. 1981; 30:1291-3.
12. Mills JN. Biodiversity loss and emerging infectious disease: an example from the rodent-borne hemorrhagic fevers. Biodiversity. 2006;7:9-17.
13. Johnson KM, Halstead SB, Cohen SN. Hemorrhagic fevers of Southeast Asia and South America: a comparative appraisal. Prog Med Virol. 1967;9:105-58.
14. de Manzione N, Salas RA, Paredes H, et al. Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. Clin Infect Dis. 1998;26:308-13.
15. Bausch DG, Ksiazek TG. Viral hemorrhagic fevers including hantavirus pulmonary syndrome in the Americas. Clin Lab Med. 2002;22:981-1020, viii.
16. Peters CJ, Zaki SR. Overview of viral hemorrhagic fevers. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens, and practice. Philadelphia: Churchill Livingstone; 2006. p. 726-33.
17. Enria DA, Mills JN, Shieh W, Bausch D, Peters CJ. Arenavirus infections. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: principles, pathogens, and practice. 3rd ed. Philadelphia: Elsevier Inc; 2011. p. 449-61.
18. Alibek K, Handelman S. Biohazard: the largest covert biological weapons program in the world. 1st ed. New York: Random House; 1999.
19. Bausch DG, Peters CJ. The viral hemorrhagic fevers. In: Lutwick LI, Lutwick SM, editors. Beyond anthrax: the weaponization of infectious diseases. New York: Humana Press; 2009. p. 107-44.
20. Gunther S, Lenz O. Lassa virus. Crit Rev Clin Lab Sci. 2004; 41:339-90.
21. Buchmeier MJ, de la Torre JC, Peters CJ. Arenaviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields' virology. 5th ed. Philadelphia: Lippincott, Williams, and Wilkins; 2006.
22. Weaver SC, Salas RA, de Manzione N, et al. Guanarito virus (Arenaviridae) isolates from endemic and outlying localities in Venezuela: sequence comparisons among and within strains isolated from Venezuelan hemorrhagic fever patients and rodents. Virology. 2000;266:189-95.
23. Fulhorst CF, Charrel RN, Weaver SC, et al. Geographic distribution and genetic diversity of Whitewater Arroyo virus in the southwestern United States. Emerg Infect Dis. 2001;7:403-7.
24. Ehichioya DU, Hass M, Becker-Ziaja B, et al. Current molecular epidemiology of Lassa virus in Nigeria. J Clin Microbiol. 2011; 49:1157-61.
25. Bowen MD, Rollin PE, Ksiazek TG, et al. Genetic diversity among Lassa virus strains. J Virol. 2000;74:6992-7004.
26. Vieth S, Torda AE, Asper M, Schmitz H, Gunther S. Sequence analysis of L RNA of Lassa virus. Virology. 2004;318:153-68.
27. Jahrling PB, Frame JD, Smith SB, Monson MH. Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates. Trans R Soc Trop Med Hyg. 1985;79:374-9.
28. Riviere Y, Ahmed R, Southern PJ, Buchmeier MJ, Oldstone MB. Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment. J Virol. 1985;55:704-9.
29. Milazzo L, Cesari M. Early viral kinetics: a novel guide for optimal dosing frequency of pegylated interferon-alpha-2a in HIV/HCVcoinfected patients. Expert Rev Anti Infect Ther. 2011;9:859-62.
30. Cao W, Henry MD, Borrow P, et al. Identification of alphadystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science. 1998;282:2079-81.
31. Choe H, Jemielity S, Abraham J, Radoshitzky SR, Farzan M. Transferrin receptor 1 in the zoonosis and pathogenesis of New World hemorrhagic fever arenaviruses. Curr Opin Microbiol. 2011; 14:476-82.
32. Rojek JM, Kunz S. Cell entry by human pathogenic arenaviruses. Cell Microbiol. 2008;10:828-35.
33. Armstrong C, Wallace J, Ross L. Lymphocytic choriomeningitis: gray mice, Mus musculus, a reservoir for the infection. Public Health Rep. 1940;55:1222-9.
34. Oldstone MB. Biology and pathogenesis of lymphocytic choriomeningitis virus infection. Curr Top Microbiol Immunol. 2002; 263:83-117.
35. Gregg MB. Recent outbreaks of lymphocytic choriomeningitis in the United States of America. Bull World Health Organ. 1975; 52:549-53.
36. Ackerman R. Epidemiologic aspects of lymphocytic choriomeningitis in man. In: Grube FL, editor. Lymphocytic choriomeningitis virus and other arenaviruses. New York: Springer; 1973. p. 233-7.
37. Brouqui P, Rousseau MC, Saron MF, Bourgeade A. Meningitis due to lymphocytic choriomeningitis virus: four cases in France. Clin Infect Dis. 1995;20:1082-3.
38. Peters CJ. Viral Infections of vertebrates, virus infections of rodents and lagomorphs. In: Horzinek MCO, A.D.M.E., editors. Arenaviruses. Amsterdam: Elsevier; 1994. p. 321-41.
39. Smith AL, Paturzo FX, Gardner EP, Morgenstern S, Cameron G, Wadley H. Two epizootics of lymphocytic choriomeningitis virus occurring in laboratory mice despite intensive monitoring programs. Can J Comp Med. 1984;48:335-7.
40. Hotchin J. The contamination of laboratory animals with lymphocytic choriomeningitis virus. Am J Pathol. 1971;64:747-69.
41. Amman BR, Pavlin BI, Albarino CG, et al. Pet rodents and fatal lymphocytic choriomeningitis in transplant patients. Emerg Infect Dis. 2007;13:719-25.
42. Childs JE, Peters CJ. Ecology and epidemiology of arenaviruses and their hosts. In: Salvato MS, editor. The arenaviridae. New York: Plenum Press; 1993. p. 331-84.
43. Childs JE, Glass GE, Ksiazek TG, Rossi CA, Oro JG, Leduc JW. Human-rodent contact and infection with lymphocytic choriomeningitis and Seoul viruses in an inner-city population. Am J Trop Med Hyg. 1991;44:117-21.
44. Gardner MB, Henderson BE, Estes JD, Menck H, Parker JC, Huebner RJ. Unusually high incidence of spontaneous lymphomas in wild house mice. J Natl Cancer Inst. 1973;50:1571-9.
45. Monath TP, Newhouse VF, Kemp GE, Setzer HW, Cacciapuoti A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science. 1974;185:263-5.
46. Bowen MD, Peters CJ, Nichol ST. Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol Phylogenet Evol. 1997;8:301-16.
47. Wulff H, Fabiyi A, Monath TP. Recent isolations of Lassa virus from Nigerian rodents. Bull World Health Organ. 1975;52:609-13.
48. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES. A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis. 1987;155:437-44.
49. Shi CX, Graham FL, Hitt MM. A convenient plasmid system for construction of helper-dependent adenoviral vectors and its application for analysis of the breast-cancer-specific mammaglobin promoter. J Gene Med. 2006;8:442-51.
50. Safronetz D, Lopez JE, Sogoba N, et al. Detection of Lassa virus, Mali. Emerg Infect Dis. 2010;16:1123-6.
51. Lecompte E, Fichet-Calvet E, Daffis S, et al. Mastomys natalensis and Lassa fever, West Africa. Emerg Infect Dis. 2006;12:1971-4.
52. Isaacson M. The ecology of Paromys (Mastomys) natalensis in southern Africa. Bull World Health Organ. 1975;52:629-36.
53. Barnett AA, Read N, Scurlock J, Low C, Norris H, Shapley R. Ecology of rodent communities in agricultural habitats in eastern Sierra Leone: cocoa groves as forest refugia. Trop Ecol. 2000;41:127-42.
54. Fichet-Calvet E, Lecompte E, Koivogui L, et al. Fluctuation of abundance and Lassa virus prevalence in Mastomys natalensis in Guinea, West Africa. Vector Borne Zoonotic Dis. 2007;7:119-28.
55. Keenlyside RA, McCormack JB, Webb PA, Smith E, Elliott L, Johnson KM. Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone. Am J Trop Med Hyg. 1983;32:829-37.
56. Demby AH, Inapogui A, Kargbo K, et al. Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals. Vector Borne Zoonotic Dis. 2001;1:283-97.
57. Bausch DG, Demby AH, Coulibaly M, et al. Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis. 2001;1:269-81.
58. McCune S, Arriola CS, Gilman RH, et al. Interspecies interactions and potential Influenza A virus risk in small swine farms in Peru. BMC Infect Dis. 2012;12:58.
59. Peters CJ, Jahrling PB, Liu CT, Kenyon RH, McKee Jr KT, Barrera Oro JG. Experimental studies of arenaviral hemorrhagic fevers. Curr Top Microbiol Immunol. 1987;134:5-68.
60. Walker DH, Wulff H, Lange JV, Murphy FA. Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull World Health Organ. 1975;52:523-34.
61. Suzuki S, Hotchin J. Initiation of persistent lymphocytic choriomeningitis infection in adult mice. J Infect Dis. 1971;123:603-10.
62. Demartini JC, Green DE, Monath TP. Lassa virus infection in Mastomys natalensis in Sierra Leone. Bull World Health Organ. 1975;52:651-63.
63. Redford KH, Eisenberg JF. Mammals of the neotropics: the southern cone. Chicago: The University of Chicago Press; 1992.
64. Mills JN, Ellis BA, McKee KTJ, et al. Junin virus activity in rodents from endemic and nonendemic loci in central Argentina. Am J Trop Med Hyg. 1991;44:589-97.
65. Ellis BA, Mills JN, Childs JE, et al. Structure and floristics of habitats associated with five rodent species in an agroecosystem in central Argentina. J Zool. 1997;243(3):437-60.
66. Mills JN, Ellis BA, McKee KT, et al. A longitudinal study of Junin virus activity in the rodent reservoir of Argentine hemorrhagic fever. Am J Trop Med Hyg. 1992;47:749-63.
67. Mills JN, Ellis BA, Childs JE, et al. Prevalence of infection with Junin virus in rodent populations in the epidemic area of Argentine hemorrhagic fever. Am J Trop Med Hyg. 1994;51:554-62.
68. Calisher CH, Sweeney W, Mills JN, Beaty BJ. Natural history of Sin Nombre virus in western Colorado. Emerg Infect Dis. 1999;5:126-34.
69. Vitullo AD, Merani MS. Vertical transmission of Junin virus in experimentally infected adult Calomys musculinus. Intervirology. 1990;31:339-44.
70. Dragoo JW, Salazar-Bravo J, Layne LJ, Yates TL. Relationships within the Calomys callosus species group based on amplified fragment length polymorphisms. Biochem Syst Ecol. 2003;31:703-13.
71. Salazar-Bravo J, Dragoo JW, Bowen MD, Peters CJ, Ksiazek TG, Yates TL. Natural nidality in Bolivian hemorrhagic fever and the systematics of reservoir species. Infect Genet Evol. 2002;1:191-9.
72. Eisenberg JF, Redford KH. Mammals of the neotropics: the central neotropics. Chicago: University of Chicago; 1999.
73. Kuns ML. Epidemiology of Machupo virus infection. II. Ecological and control studies of hemorrhagic fever. Am J Trop Med Hyg. 1965;14:813-6.
74. Johnson KM. Epidemiology of Machupo virus infection. III. Significance of virological observations in man and animals. Am J Trop Med Hyg. 1965;14:816-8.
75. Johnson KM. Arenaviruses. In: Evans AS, editor. Viral infections of humans. New York: Plenum Medical Book Company; 1989. p. 133-52.
76. Anderson JF, Johnson RC, Magnarelli LA, Hyde FW. Identification of endemic foci of lyme disease: isolation of borrelia burgdorferi from feral rodents and ticks. J Clin Microbiol. 1985;22:36-8.
77. Aleman A, Iguaran H, Puerta H, et al. Primera evidencia serologica de infeccion por hantavirus in roedores en Colombia. Revista de Salud Publica (Colombia). 2006;8:1-12.
78. Johnson KM. Arenaviruses. In: Fields BN, Knipe KN, editors. Virology. New York: Raven; 1985. p. 1033-53.
79. Fulhorst CF, Bowen MD, Salas RA, et al. Natural rodent host associations of guanarito and pirital viruses (family Arenaviridae) in central Venezuela. Am J Trop Med Hyg. 1999;61:325-30.
80. Milazzo ML, Cajimat MN, Duno G, Duno F, Utrera A, Fulhorst CF. Transmission of Guanarito and Pirital viruses among wild rodents, Venezuela. Emerg Infect Dis. 2011;17:2209-15.
81. Musser GG, Carleton MD. Superfamily Muroidea. In: Wilson DE, Reeder DM, editors. Mammal species of the world, a taxonomic and geographic reference. Baltimore: Johns Hopkins University Press; 2005. p. 894-1531.
82. Utrera A, Duno G, Ellis BA, et al. Small mammals in agricultural areas of the western llanos of Venezuela: community structure, habitat associations, and relative densities. J Mammal. 2000;81:536-48.
83. Fulhorst CF, Ksiazek T, Peters CJ, Tesh RB. Experimental infection of the cane mouse Zygodontomys brevicauda (Family Muridae) with Guanarito Virus (Arenaviridae), the etiologic agent of Venezuelan hemorrhagic fever. J Infect Dis. 1999;180:966-9.
84. Downs WG, Anderson CR, Spence L, Aitken THG, Greenhall AH. Tacaribe virus, a new agent isolated from Artibeus bats and mosquitos in Trinidad, West Indies. Am J Trop Med Hyg. 1963;12:640-6.
85. Cogswell-Hawkinson A, Bowen R, James S, et al. Tacaribe virus causes fatal infection of an ostensible reservoir host, the Jamaican fruit bat. J Virol. 2012;86:5791-9.
86. Stenglein MD, Sanders C, Kistler AL, et al. Identification, characterization, and in vitro culture of highly divergent arenaviruses from boa constrictors and annulated tree boas: candidate etiological agents for snake inclusion body disease. MBio. 2012;3: e00180-12.
87. Stephenson EH, Larson EW, Dominik JW. Effect of environmental factors on aerosol-induced Lassa virus infection. J Med Virol. 1984;14:295-303.
88. Leffel EK, Reed DS. Marburg and Ebola viruses as aerosol threats. Biosecur Bioterror. 2004;2:186-91.
89. Kenyon RH, McKee Jr KT, Zack PM, et al. Aerosol infection of rhesus macaques with Junin virus. Intervirology. 1992;33:23-31.
90. Reed DS, Lackemeyer MG, Garza NL, Sullivan LJ, Nichols DK. Aerosol exposure to Zaire ebola virus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect. 2011;13:930-6.
91. Rai SK, Micales BK, Wu MS, et al. Timed appearance of lymphocytic choriomeningitis virus after gastric inoculation of mice. Am J Pathol. 1997;151:633-9.
92. Lukashevich IS, Djavani M, Rodas JD, et al. Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J Med Virol. 2002;67:171-86.
93. ter Meulen J, Lukashevich I, Sidibe K, et al. Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am J Trop Med Hyg. 1996;55:661-6.
94. Armstrong C, Lillie RD. Experimental lymphocytic choriomeningitis of monkeys and mice produced by a virus encountered in studies of the 1933 St. Louis encephalitis epidemic. Publ Health Rep. 1934;49:1019-27.
95. Lehmann-Grube F. Lymphocytic choriomeningitis virus. In: Virology monographs. Vienna/New York: Springer; 1971.
96. Ambrosio AM, Feuillade MR, Gamboa GS, Maiztegui JI. Prevalence of lymphocytic choriomeningitis virus infection in a human population of Argentina. Am J Trop Med Hyg. 1994;50: 381-6.
97. Park JY, Peters CJ, Rollin PE, et al. Age distribution of lymphocytic choriomeningitis virus serum antibody in Birmingham, Alabama: evidence of a decreased risk of infection. Am J Trop Med Hyg. 1997;57:37-41.
98. Armstrong C. Studies on choriomeningitis and poliomyelitis: Harvey Lecture, October 31, 1940. Bull N Y Acad Med. 1941;17:295-318.
99. Adair CV, Gauld RL, Smadel JE. Aseptic meningitis, a disease of diverse etiology: clinical and etiologic studies on 854 cases. Ann Intern Med. 1953;39:675-704.
100. Meyer Jr HM, Johnson RT, Crawford IP, Dascomb HE, Rogers NG. Central nervous system syndromes of "vital" etiology. A study of 713 cases. Am J Med. 1960;29:334-47.
101. Glaser CA, Gilliam S, Schnurr D, et al. In search of encephalitis etiologies: diagnostic challenges in the California Encephalitis Project, 1998-2000. Clin Infect Dis. 2003;36:731-42.
102. Davison KL, Crowcroft NS, Ramsay ME, Brown DW, Andrews NJ. Viral encephalitis in England, 1989-1998: what did we miss? Emerg Infect Dis. 2003;9:234-40.
103. Blumenthal W, Ackermann R, Scheid W. Distribution of the lymphocytic choriomeningitis virus in an endemic area. Dtsch Med Wochenschr. 1968;93:944-8.
104. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med. 2006;354:2235-49.
105. Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med. 2008; 358:991-8.
106. Frame JD, Baldwin Jr JM, Gocke DJ, Troup JM. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am J Trop Med Hyg. 1970;19:670-6.
107. Rose JR. Letters to the editor: a new clinical entity. Lancet. 1956; 2:197.
108. Monath TP, Maher M, Casals J, Kissling RE, Cacciapuoti A. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg. 1974;23:1140-9.
109. Monath TP, Mertens PE, Patton R, et al. A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg. 1973;22:773-9.
110. Richmond JK, Baglole DJ. Lassa fever: epidemiology, clinical features, and social consequences. BMJ. 2003;327:1271-5.
111. Fichet-Calvet E, Rogers DJ. Risk maps of Lassa fever in West Africa. PLoS Negl Trop Dis. 2009;3:e388.
112. Bloch A. A serological survey of Lassa fever in Liberia. Bull World Health Organ. 1978;56:811-3.
113. Ehichioya DU, Hass M, Olschlager S, et al. Lassa fever, Nigeria, 2005-2008. Emerg Infect Dis. 2010;16:1040-1.
114. McCormick JB, King IJ, Webb PA, et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis. 1987; 155:445-55.
115. Fair J, Jentes E, Inapogui A, et al. Lassa virus-infected rodents in refugee camps in Guinea: a looming threat to public health in a politically unstable region. Vector Borne Zoonotic Dis. 2007;7: 167-71.
116. Hotchin J, Kinch W, Benson L. Lytic and turbid plaque-type mutants of lymphocytic choriomeningitis virus as a cause of neurological disease or persistent infection. Infect Immun. 1971;4: 281-6.
117. Khan S, Goba A, Chu M, et al. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Res. 2008;78:103-15.
118. Carey DE, Kemp GE, White HA, et al. Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria. Trans R Soc Trop Med Hyg. 1972;66:402-8.
119. Bausch DG, Rollin PE, Demby AH, et al. Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation. J Clin Microbiol. 2000;38:2670-7.
120. Van der Waals FW, Pomeroy KL, Goudsmit J, Asher DM, Gajdusek DC. Hemorrhagic fever virus infections in an isolated rainforest area of central Liberia. Limitations of the indirect immunofluorescence slide test for antibody screening in Africa. Trop Geogr Med. 1986;38:209-14.
121. Bonner PC, Schmidt W-P, Belmain SR, Oshin B, Baglole D, Borchert M. Poor housing quality increases risk of rodent infestation and Lassa fever in refugee camps of Sierra Leone. Am J Trop Med Hyg. 2007;77:169-75.
122. Fisher-Hoch SP, Tomori O, Nasidi A, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ. 1995;311:857-9.
123. Maiztegui JI, Briggiler A, Feuillade MR. Progressive extension of the endemic area and changing incidence of Argentine hemorrhagic fever. Med Microbiol Immunol. 1986;175:149-52.
124. Health AMo. Report for 26th Annual Meeting of the National Program for Control of Argentine Hemorrhagic Fever. Buenos Aires: Argentine Ministry of Health; 2011.
125. Centers for Disease Control and Prevention (CDC). Bolivian hemorrhagic feve-l Beni Department, Bolivia, 1994. MMWR Morb Mortal Wkly Rep. 1994;43:943-6.
126. Salas R, de Manzione N, Tesh RB, et al. Venezuelan haemorrhagic fever-A severe multisystem illness caused by a newly recognized arenavirus. Lancet. 1991;338:1033-6.
127. Coimbra TLM, Nassar ES, Burattini MN, et al. New arenavirus isolated in Brazil. Lancet. 1994;343:391-2.
128. Milazzo ML, Campbell GL, Fulhorst CF. Novel arenavirus infection in humans, United States. Emerg Infect Dis. 2011;17: 1417-20.
129. Update on Lassa fever in West Africa. WHO. 2005. http://who.int/ csr/don/2004-03-11/en/print/html. Accessed 11 Mar 2005.
130. Boumandouki P, Formenty P, Epelboin A, et al. Clinical management of patients and deceased during the Ebola outbreak from October to December 2003 in Republic of Congo. Bull Soc Pathol Exot. 2005;98:218-23.
131. Leifer E, Gocke DJ, Bourne H. Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease. Am J Trop Med Hyg. 1970;19:677-9.
132. Emond RT, Bannister B, Lloyd G, Southee TJ, Bowen ET. A case of Lassa fever: clinical and virological findings. Br Med J (Clin Res Ed). 1982;285:1001-2.
133. Lunkenheimer K, Hufert FT, Schmitz H. Detection of Lassa virus RNA in specimens from patients with Lassa fever by using the polymerase chain reaction. J Clin Microbiol. 1990;28:2689-92.
134. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, King IJ. Clinical virology of Lassa fever in hospitalized patients. J Infect Dis. 1987;155:456-64.
135. Zweighaft RM, Fraser DW, Hattwick MA, et al. Lassa fever: response to an imported case. N Engl J Med. 1977;297:803-7.
136. Douglas RGW, Wiebenga NH, Couch RB. Bolivian hemorrhagic fever probably transmitted by personal contact. Am J Epidemiol. 1965;82:85-91.
137. Kilgore PE, Peters CJ, Mills JN, et al. Prospects for the control of Bolivian hemorrhagic fever. Emerg Infect Dis. 1995;1:97-100.
138. Peters CJ, Kuehne RW, Mercado RR, Le Bow RH, Spertzel RO, Webb PA. Hemorrhagic fever in Cochabamba, Bolivia, 1971. Am J Epidemiol. 1974;99:425-33.
139. ter Meulen J, Lenz O, Koivogui L, et al. Short communication: Lassa fever in Sierra Leone: UN peacekeepers are at risk. Trop Med Int Health. 2001;6:83-4.
140. Haas WH, Breuer T, Pfaff G, et al. Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis. 2003;36:1254-8.
141. Vanzee BE, Douglas RG, Betts RF, Bauman AW, Fraser DW, Hinman AR. Lymphocytic choriomeningitis in university hospital personnel. Clinical features. Am J Med. 1975;58:803-9.
142. Solbrig MV, McCormick JB. Lassa fever: central nervous system manifestations. J Trop Geogr Neurol. 1991;1:23-30.
143. Walker DH, McCormick JB, Johnson KM, et al. Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol. 1982;107:349-56.
144. Monson MH, Cole AK, Frame JD, Serwint JR, Alexander S, Jahrling PB. Pediatric Lassa fever: a review of 33 Liberian cases. Am J Trop Med Hyg. 1987;36:408-15.
145. Bausch DG. 389: Viral hemorrhagic fevers. In: Goldman L, Schafer A, editors. Goldman's Cecil medicine. 24th ed. 2011. p. 2704.
146. Ketai L, Alrahji AA, Hart B, Enria D, Mettler Jr F. Radiologic manifestations of potential bioterrorist agents of infection. AJR Am J Roentgenol. 2003;180:565-75.
147. Cummins D, Bennett D, Fisher-Hoch SP, Farrar B, McCormick JB. Electrocardiographic abnormalities in patients with Lassa fever. J Trop Med Hyg. 1989;92:350-5.
148. Branco LM, Matschiner A, Fair JN, et al. Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance. Virol J. 2008;5:74.
149. Saijo M, Georges-Courbot MC, Marianneau P, et al. Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever. Clin Vaccine Immunol. 2007;14:1182-9.
150. de Souza MS, Smith AL. Comparison of isolation in cell culture with conventional and modified mouse antibody production tests for detection of murine viruses. J Clin Microbiol. 1989;27: 185-7.
151. Deibel R, Schryver GD. Viral antibody in the cerebrospinal fluid of patients with acute central nervous system infections. J Clin Microbiol. 1976;3:397-401.
152. Zaki SR, Shieh WJ, Greer PW, et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179 Suppl 1:S36-47.
153. Niedrig M, Schmitz H, Becker S, et al. First international quality assurance study on the rapid detection of viral agents of bioterrorism. J Clin Microbiol. 2004;42:1753-5.
154. Marty AM, Jahrling PB, Geisbert TW. Viral hemorrhagic fevers. Clin Lab Med. 2006;26:345-86, viii.
155. Rodas JD, Lukashevich IS, Zapata JC, et al. Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever. J Med Virol. 2004;72:424-35.
156. Fisher-Hoch SP, McCormick JB, Auperin D, et al. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc Natl Acad Sci U S A. 1989;86:317-21.
157. Jahrling PB, Frame JD, Rhoderick JB, Monson MH. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg. 1985;79:380-4.
158. Schmitz H, Kohler B, Laue T, et al. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect. 2002;4:43-50.
159. Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. Effective vaccine for Lassa fever. J Virol. 2000;74:6777-83.
160. Jahrling PB, Niklasson BS, McCormick JB. Early diagnosis of human Lassa fever by ELISA detection of antigen and antibody. Lancet. 1985;1:250-2.
161. Bond N, Schieffelin JS, Moses LM, Bennett AJ, Bausch DG. A historical look at the first reported cases of Lassa fever: IgG antibodies 40 years after acute infection. Am J Trop Med Hyg. 2013;88(2):241-4.
162. Sabeti PC, Varilly P, Fry B, et al. Genome-wide detection and characterization of positive selection in human populations. Nature. 2007;449:913-8.
163. Dey M, Telser J, Kunz RC, Lees NS, Ragsdale SW, Hoffman BM. Biochemical and spectroscopic studies of the electronic structure and reactivity of a methyl-Ni species formed on methyl-coenzyme M reductase. J Am Chem Soc. 2007;129:11030-2.
164. Ballenger-Browning KK, Elder JP. Multi-modal Aedes aegypti mosquito reduction interventions and dengue fever prevention. Trop Med Int Health. 2009;14:1542-51.
165. Ellis BR, Wilcox BA. The ecological dimensions of vector-borne disease research and control. Cad Saude Publica. 2009;25 Suppl 1:S155-67.
166. Kelly DJ, Barrie MB, Ross RA, Temple BA, Moses LM, Bausch DG. Housing equity for health equity: a rights-based approach to the control of Lassa fever in post-war Sierra Leone. BMC Int Health Hum Rights. 2013;13:2.
167. Peters CJ. Emerging infections: lessons from the viral hemorrhagic fevers. Trans Am Clin Climatol Assoc. 2006;117:189-96; discussion 96-7.
168. Belanov EF, Muntyanov VP, Kryuk D, et al. Survival of Marburg virus on contaminated surfaces and in aerosol. Russian Progress Virol. 1997;1:47-50.
169. Pfau CJ. Biochemical and biophysical properties of the arenaviruses. Prog Med Virol. 1974;18:64-80.
170. Sagripanti JL, Rom AM, Holland LE. Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces. Arch Virol. 2010;155:2035-9.
171. Bazhutin NB, Belanov EF, Spiridonov VA, et al. The influence of the methods of experimental infection with Marburg virus on the course of illness in green monkeys (Russian). Vopr Virusol. 1992;37:153-6.
172. Chepurnov AA, Chuev Iu P, P'Iankov OV, Efimova IV. The effect of some physical and chemical factors on inactivation of the Ebola virus (Russian). Vopr Virusol. 1995;40:74-6.
173. Chepurnov AA, Bakulina LF, Dadaeva AA, Ustinova EN, Chepurnova TS, Baker Jr JR. Inactivation of Ebola virus with a surfactant nanoemulsion. Acta Trop. 2003;87:315-20.
174. Lupton HW. Inactivation of Ebola virus with 60Co irradiation. J Infect Dis. 1981;143:291.
175. Logan JC, Fox MP, Morgan JH, Makohon AM, Pfau CJ. Arenavirus inactivation on contact with N-substituted isatin betathiosemicarbazones and certain cations. J Gen Virol. 1975;28: 271-83.
176. Mitchell SW, McCormick JB. Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses. J Clin Microbiol. 1984;20:486-9.
177. Saluzzo JF, Leguenno B, Van der Groen G. Use of heat inactivated viral haemorrhagic fever antigens in serological assays. J Virol Methods. 1988;22:165-72.
178. Kraus AA, Priemer C, Heider H, Kruger DH, Ulrich R. Inactivation of Hantaan virus-containing samples for subsequent investigations outside biosafety level 3 facilities. Intervirology. 2005;48: 255-61.
179. Warfield KL, Swenson DL, Olinger GG, et al. Ebola Virus Inactivation with Preservation of Antigenic and Structural Integrity by a Photoinducible Alkylating Agent. J Infect Dis. 2007;196:S276-83.
180. Maes P, Li S, Verbeeck J, Keyaerts E, Clement J, Van Ranst M. Evaluation of the efficacy of disinfectants against Puumala hantavirus by real-time RT-PCR. J Virol Methods. 2007;141:111-5.
181. Lytle CD, Sagripanti JL. Predicted inactivation of viruses of relevance to biodefense by solar radiation. J Virol. 2005;79:14244-52.
182. Sagripanti JL, Routson LB, Lytle CD. Virus inactivation by copper or iron ions alone and in the presence of peroxide. Appl Environ Microbiol. 1993;59:4374-6.
183. Sagripanti JL, Lytle CD. Sensitivity to ultraviolet radiation of Lassa, vaccinia, and Ebola viruses dried on surfaces. Arch Virol. 2011;156(3):489-94.
184. Garcia CC, Ellenberg PC, Artuso MC, Scolaro LA, Damonte EB. Characterization of Junin virus particles inactivated by a zinc finger-reactive compound. Virus Res. 2009;143:106-13.
185. WHO, CDC. Infection control for viral haemorrhagic fevers in the African health care setting. Atlanta: Centers for Disease Control and Prevention; 1998.
186. Mills JN, Corneli A, Young JC, Garrison LE, Khan AS, Ksiazek TG. Hantavirus pulmonary syndrome-United States: updated recommendations for risk reduction. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51:1-12.
187. Centers for Disease Control and Prevention (CDC). Update: interim guidance for minimizing risk for human lymphocytic choriomeningitis virus infection associated with pet rodents. MMWR Morb Mortal Wkly Rep. 2005;54:799-801.
188. The National Personal Protective Technology Laboratory (NPPTL): NIOSH-Approved Particulate Filtering Facepiece Respirators. Centers for Disease Control and Prevention. 2012. http://www.cdc.gov/niosh/npptl/topics/respirators/disp-part/ default.html. Accessed 15 July 2013.
189. Fulhorst CF, Milazzo ML, Armstrong LR, et al. Hantavirus and arenavirus antibodies in persons with occupational rodent exposure. Emerg Infect Dis. 2007;13:532-8.
190. Mills J, Yates T, Childs J, et al. Guidelines for working with rodents potentially infected with hantavirus. J Mammal. 1995;76: 716-22.
191. Reed KD, Melski JW, Graham MB, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med. 2004;350:342-50.
192. Ambrosio A, Saavedra M, Mariani M, Gamboa G, Maiza A. Argentine hemorrhagic fever vaccines. Hum Vaccin. 2011;7:694-700.
193. McCormick JB, Mitchell SW, Kiley MP, Ruo S, Fisher-Hoch SP. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J Med Virol. 1992;37:1-7.
194. Bergthaler A, Gerber NU, Merkler D, Horvath E, de la Torre JC, Pinschewer DD. Envelope exchange for the generation of liveattenuated arenavirus vaccines. PLoS Pathog. 2006;2:e51.
195. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol. 2001; 75:11677-85.
196. Asper M, Sternsdorf T, Hass M, et al. Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus. J Virol. 2004;78:3162-9.
197. Firsova IV, Shatokhina IV, Borisevich IV, et al. Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever. Vopr Virusol. 2003;48:43-5.
198. Grant-Klein RJ, Altamura LA, Schmaljohn CS. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses. Virus Res. 2011;162:148-61.
199. Bredenbeek PJ, Molenkamp R, Spaan WJ, et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology. 2006;345:299-304.
200. Jiang X, Dalebout TJ, Bredenbeek PJ, et al. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine. 2011;29:1248-57.
201. Lukashevich IS, Carrion Jr R, Salvato MS, et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine. 2008;26: 5246-54.
202. Lukashevich IS, Patterson J, Carrion R, et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol. 2005;79:13934-42.
203. Carrion Jr R, Patterson JL, Johnson C, et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine. 2007;25:4093-102.
204. Branco LM, Grove JN, Geske FJ, et al. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J. 2010; 7:279.
205. Geisbert TW, Jones S, Fritz EA, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005;2:e183.
206. Falzarano D, Feldmann F, Grolla A, et al. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. J Infect Dis. 2011;204 Suppl 3:S1082-9.
207. Hopkins AS, Whitetail-Eagle J, Corneli AL, et al. Experimental evaluation of rodent exclusion methods to reduce hantavirus transmission to residents in a Native American community in New Mexico. Vector Borne Zoonotic Dis. 2002;2:61-8.
208. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 2008; 4:e1000225.
209. Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis. 2010;51:1435-41.
210. Blumberg L, Enria D, Bausch DG. Viral haemorrhagic fevers. In: Farrar J et al., editors. Manson's tropical diseases. 23rd ed. Philadelphia: Elsevier Publishing; 2013.